Andrew Weickhardt
Olivia Newton-John Cancer Wellness & Research Centre(AU)Austin Health(AU)
Publications by Year
Research Areas
Prostate Cancer Treatment and Research, Radiopharmaceutical Chemistry and Applications, Cancer Immunotherapy and Biomarkers, Fibroblast Growth Factor Research, Lung Cancer Treatments and Mutations
Most-Cited Works
- → Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer(2012)1,061 cited
- → [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial(2021)1,014 cited
- → Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer(2012)669 cited
- → Oncogene status predicts patterns of metastatic spread in treatment‐naive nonsmall cell lung cancer(2012)279 cited
- → PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial(2022)242 cited
- → Stereotactic Radiation Therapy can Safely and Durably Control Sites of Extra-Central Nervous System Oligoprogressive Disease in Anaplastic Lymphoma Kinase-Positive Lung Cancer Patients Receiving Crizotinib